Dichotomy between Cosentyx and Stelara: Uncovering their key distinctions
In the treatment of plaque psoriasis and psoriatic arthritis, two popular biologic drugs are Cosentyx (secukinumab) and Stelara (ustekinumab). Both are approved for use in children and adults, but their mechanisms, efficacy, safety, cost, and dosage vary.
Mechanism of Action
Cosentyx, an IL-17A inhibitor, targets the interleukin-17 pathway, which plays a significant role in the inflammation and keratinocyte proliferation seen in psoriasis. On the other hand, Stelara is an IL-12/23 inhibitor, blocking both interleukin-12 and interleukin-23, cytokines involved in immune activation and inflammation.
Efficacy
In adults, both drugs are highly effective compared to conventional therapies for moderate-to-severe plaque psoriasis. Recent comparative effectiveness studies suggest that Cosentyx may achieve higher PASI100 and PASI90 response rates than Stelara, with superior long-term efficacy and durability. For psoriatic arthritis, both are effective, but Stelara has broader evidence, while Cosentyx is sometimes preferred for patients with enthesitis or axial involvement due to IL-17’s role in these domains.
Pediatric use is approved for Cosentyx (ages 6 and up, ≥20 kg) and Stelara (ages 6 and up), but pediatric data for psoriatic arthritis are more limited, and their effectiveness and safety are extrapolated from adult data, pending more specific pediatric trials.
Safety
Common adverse effects for Cosentyx include upper respiratory infections, nasopharyngitis, and diarrhea. IL-17 inhibitors are associated with a higher risk of Candida infections and very rarely inflammatory bowel disease exacerbation. Stelara's common side effects include upper respiratory infections, headache, and fatigue. IL-12/23 inhibition may theoretically increase infection risk, but Stelara has a favorable long-term safety profile, with less risk of Candida or inflammatory bowel disease exacerbation compared to IL-17 inhibitors.
Cost
Cosentyx, as a newer biologic, has high list prices, but biosimilars for other classes have driven down costs in the broader psoriasis/psoriatic arthritis market. Stelara's cost is higher but is now facing emerging biosimilar competition, which may lower prices over time. The actual cost to patients depends heavily on insurance coverage, formulary placement, and copay assistance.
Dosage
The recommended dosage for Cosentyx and Stelara for plaque psoriasis and psoriatic arthritis in children varies based on body weight:
- Less than 60 kg (about 132 lb): 0.75 mg/kg for Stelara; 45 mg for Cosentyx (60 to 100 kg or 132 to 220 lb)
- Greater than 100 kg (about 220 lb): 90 mg for Stelara; not applicable for Cosentyx (as it is dosed based on body weight)
- 50 kg or more: 150 mg for Cosentyx
- 15 kg to less than 50 kg: 75 mg for Cosentyx
Key Conclusions
- Efficacy: Cosentyx may offer higher skin clearance rates in plaque psoriasis, especially over longer periods, while both are effective for psoriatic arthritis.
- Safety: Both are generally safe, but Cosentyx carries a higher risk of Candida infections; Stelara may be preferred in patients with a history of inflammatory bowel disease.
- Cost: Both are expensive, but biosimilar competition is beginning to impact Stelara’s pricing, whereas Cosentyx’s cost remains elevated. Actual patient cost depends heavily on insurance and formulary status.
- Pediatric Use: Both are approved for pediatric plaque psoriasis; evidence for psoriatic arthritis in children is more limited.
Treatment choice should be individualized, considering efficacy, safety, cost, and patient-specific factors. It's essential to consult a doctor or healthcare professional before taking any medication. Serious side effects of both drugs include new or worsening inflammatory bowel disease, increased risk of cancers, depression, a rare brain condition called reversible posterior leukoencephalopathy syndrome, serious allergic reactions, and serious infections. Switching between Cosentyx and Stelara is possible, but it's important to discuss this with your doctor.
For more detailed information about dosage, forms, and administration, see the Cosentyx and Stelara articles.
- The mechanisms of Cosentyx and Stelara, two popular treatments for plaque psoriasis and psoriatic arthritis, differ significantly as Cosentyx is an IL-17A inhibitor, while Stelara is an IL-12/23 inhibitor.
- In the treatment of moderate-to-severe plaque psoriasis in adults, both Cosentyx and Stelara have high efficacy compared to conventional therapies, but Cosentyx may achieve higher PASI100 and PASI90 response rates with greater long-term efficacy and durability.
- For psoriatic arthritis, both drugs are effective, but Stelara has broader evidence while Cosentyx is sometimes preferred for patients with enthesitis or axial involvement.
- In terms of safety, common side effects of Cosentyx include upper respiratory infections, nasopharyngitis, and diarrhea, while Stelara's common side effects include upper respiratory infections, headache, and fatigue.
- IL-17 inhibitors, like Cosentyx, carry a higher risk of Candida infections and rare inflammatory bowel disease exacerbation, whereas Stelara has a more favorable long-term safety profile with less risk of Candida or inflammatory bowel disease exacerbation.
- Given their high list prices, both Cosentyx and Stelara are expensive, but biosimilar competition is affecting Stelara’s pricing, whereas Cosentyx's cost remains elevated; actual patient cost depends heavily on insurance coverage and formulary placement.
- Approval for pediatric use of Cosentyx and Stelara for plaque psoriasis is established, but evidence for psoriatic arthritis in children is more limited and based on extrapolation from adult data.
- In selecting treatment, the consideration of efficacy, safety, cost, and patient-specific factors is important, and it is essential to consult a doctor or healthcare professional before taking any medication.
- Switching between Cosentyx and Stelara is possible, but this decision should be discussed with your doctor, as serious side effects include new or worsening inflammatory bowel disease, increased risk of cancers, depression, a rare brain condition, serious allergic reactions, and serious infections. For comprehensive information on dosage, forms, and administration, refer to the articles on Cosentyx and Stelara in the realm of science, medical-conditions, health-and-wellness, skin-care, therapies-and-treatments, and potentially CBD if applicable.
